PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 93 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $165,299 | +15248.1% | 9,910 | +25310.3% | 0.00% | – |
Q2 2023 | $1,077 | -88.0% | 39 | -96.5% | 0.00% | – |
Q3 2022 | $9,000 | -18.2% | 1,112 | +136.6% | 0.00% | – |
Q1 2022 | $11,000 | +10.0% | 470 | +69.1% | 0.00% | – |
Q4 2021 | $10,000 | +150.0% | 278 | +5.3% | 0.00% | – |
Q3 2021 | $4,000 | -75.0% | 264 | -25.6% | 0.00% | – |
Q2 2021 | $16,000 | +77.8% | 355 | 0.0% | 0.00% | – |
Q1 2021 | $9,000 | 0.0% | 355 | -17.1% | 0.00% | – |
Q4 2020 | $9,000 | +800.0% | 428 | +601.6% | 0.00% | – |
Q3 2020 | $1,000 | 0.0% | 61 | 0.0% | 0.00% | – |
Q2 2020 | $1,000 | – | 61 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |